Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
481-500 of 2,251 trials

Small Bowel Adenocarcinoma: FOLFIRINOX vs. FOLFOX

We are studying two chemotherapy treatments for patients with locally advanced or metastatic small bowel adenocarcinoma. The goal is to find out which treatment helps patients live longer without their cancer worsening.

Small Bowel Adenocarcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Sparsentan for Pediatric Kidney Diseases

We are studying a new oral treatment for children with certain kidney diseases to see if it is safe and effective. The trial will also evaluate how well children tolerate the medication and its impact on kidney function.

Proteinuric Glomerular Diseases>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Primary Aldosteronism: [68Ga]Ga-PentixaFor PET Imaging Study

We are evaluating a new imaging method to help identify how adrenal glands secrete aldosterone in patients with primary aldosteronism. This may improve diagnosis and treatment options for those affected.

Primary Hyperaldosteronism>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinology

B-cell Non-Hodgkin Lymphoma: CARCIK-CD19 Cell Therapy

We are studying a new cell therapy for adults and children with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The trial aims to evaluate the safety and effectiveness of this treatment.

B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Acute Myeloid Leukemia: Comparing Conditioning Regimens in Children

We are studying two different treatment plans for children with Acute Myeloid Leukemia undergoing stem cell transplants. Our goal is to find out which plan leads to better survival and fewer side effects.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Giant Cell Arteritis: Stopping Tocilizumab

We are comparing immediate versus gradual stopping of tocilizumab in patients with giant cell arteritis. The goal is to see which method helps prevent relapses and improves quality of life.

Giant Cell Arteritis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesRheumatology

Long-term Safety Study for Ciltacabtagene Autoleucel

We are following up with patients who received cilta-cel to learn about any long-term side effects and how well the treatment works over time. This study aims to improve our understanding of the treatment's safety and effectiveness.

Multiple Myeloma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Metastatic Colorectal Cancer: LB-100 and Atezolizumab Study

We are investigating a new combination of medications for patients with metastatic colorectal cancer to see if it is safe and effective. This study aims to find the best dose and understand how well the treatment works.

Microsatellite Stable Colorectal Cancer>2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Ceftazidime-Avibactam for Critically Ill Patients

We are studying the best dosing of ceftazidime-avibactam for critically ill patients on continuous renal replacement therapy. This research aims to improve treatment effectiveness and safety.

Ceftazidime-avibactam Therapy1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNephrology

Hereditary Ichthyosis: Injectable Gentamicin Study

We are studying whether injectable gentamicin can improve skin scaling and redness in people with hereditary ichthyosis. This trial aims to assess its effects on skin condition and overall quality of life.

Congenital Ichthyosis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesDermatology

Refractory Heart Failure: Dapagliflozin Study

We are investigating how Dapagliflozin may help patients with refractory heart failure eliminate sodium and manage fluid levels during peritoneal dialysis. This study aims to improve treatment options for these patients.

Refractory Heart Failure≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineNephrology

Immune Thrombocytopenia: Avatrombopag vs. Rituximab

We are comparing the effectiveness of Avatrombopag and Rituximab in adults with ITP who did not respond to corticosteroids. The study aims to see which treatment better improves health-related quality of life and reduces fatigue.

Immune Thrombocytopenia1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInternal Medicine

Carcinoma of Unknown Primary: [18F]F-FAPI PET-CT Study

We are investigating whether [18F]F-FAPI PET-CT can help identify the primary tumor in patients with carcinoma of unknown primary. This study aims to improve diagnosis and treatment options for these patients.

Carcinoma of Unknown Primary>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Spinal Muscular Atrophy: Risdiplam Study for Infants

We are investigating how the medication risdiplam works and its safety in infants with spinal muscular atrophy. This study aims to provide important insights into its use for this condition.

Spinal Muscular Atrophy1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Posaconazole for Young Children with Fungal Infections

We are studying how well Posaconazole works and its safety in children under 2 years old with invasive fungal infections. This research will help us understand its effects compared to older patients.

Fungal Infection3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPediatrics

Trastuzumab Deruxtecan (T-DXd) for Unresectable or Metastatic HER2-low Breast Cancer

We are studying the effects of T-DXd in patients with hormone receptor-negative and hormone receptor-positive HER2-low breast cancer. The goal is to see if it can improve treatment outcomes compared to current options.

Advanced Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Richter's Syndrome: M-CHOP with Mosunetuzumab

We are studying a new treatment combining mosunetuzumab with CHOP for patients with Richter's Syndrome who have not had therapy before. The aim is to evaluate its effectiveness and safety.

Richter's Syndrome1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

B-Cell Non-Hodgkin’s Lymphoma: Glofitamab and Obinutuzumab Study

We are studying the safety and effectiveness of Glofitamab alone and with Obinutuzumab in patients with relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. This trial aims to find the best dose and understand how these treatments work together.

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Atypical Hemolytic Uremic Syndrome: Crovalimab for Kids

We are studying the safety and effectiveness of crovalimab in children with atypical hemolytic uremic syndrome. This trial includes both new patients and those switching from other treatments.

Atypical Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyNephrology

Cholangiocarcinoma: Tinengotinib Study

We are studying the safety and effectiveness of a new oral medication, tinengotinib, for patients with FGFR-altered cholangiocarcinoma that hasn't responded to other treatments. This trial compares tinengotinib to the physician's choice of treatment.

Cholangiocarcinoma6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology